Immunobiology of chronic lung allograft dysfunction: new insights from the bench and beyond.
The first successful human lung transplants were performed in the 1980s. Since that time lung transplantation has been a therapeutic modality for end-stage pulmonary diseases. However, chronic rejection, known as obliterative bronchiolitis (OB)/bronchiolitis obliterans syndrome (BOS), is the key reason why the 5-year survival is only 50%, which is significantly worse than most other solid organ transplants. Recent studies have provided exciting advances that are beginning to be translated into findings in humans. This review will highlight the current advances in understanding the mechanisms of OB/BOS in lung transplant recipients.
Shilling
R A
RA
Section of Pulmonary and Critical Care Medicine, Department of Medicine and Committee on Immunology, University of Chicago, Chicago, IL, USA.
Wilkes
D S
DS
D015551:Autoimmunity / Q000276:immunology; D001989:Bronchiolitis Obliterans / Q000453:epidemiology*; D006801:Humans; D008168:Lung / Q000276:immunology / Q000503:physiopathology*; D016040:Lung Transplantation / Q000276:immunology*; D012307:Risk Factors; D014184:Transplantation, Homologous